Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Blueprint Medicines
Pharma
After Roche breakup, Blueprint finds Gavreto a new home at Rigel
Gavreto generated about $28 million in U.S. sales last year, versus $175 million by Eli Lilly's rival drug Retevmo.
Angus Liu
Feb 22, 2024 10:33am
Blueprint boosts Ayvakit peak sales estimate to $2B
Feb 15, 2024 7:00am
JPM24, Day 1: BMS, Amgen, Regeneron and more
Jan 8, 2024 4:18pm
Lilly pressures Blueprint further with positive NSCLC readout
Aug 4, 2023 10:40am
Roche pulls a Gavreto cancer indication, citing unfeasible trial
Jul 5, 2023 12:16pm
Alexis Borisy loses majority investor support at Blueprint
Jun 28, 2023 11:16am